{"id":"NCT01084148","sponsor":"Orfagen","briefTitle":"Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis","officialTitle":"Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2009-01","completion":"2009-03","firstPosted":"2010-03-10","resultsPosted":"2014-03-18","lastUpdate":"2017-12-20"},"enrollment":237,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Uremic Xerosis"],"interventions":[{"type":"DRUG","name":"V0034CR01B","otherNames":[]},{"type":"DRUG","name":"V0034CR01B vehicle","otherNames":[]}],"arms":[{"label":"V0034CR01B","type":"EXPERIMENTAL"},{"label":"V0034 CR 01B vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"Primary objective:\n\nTo demonstrate the long-term efficacy (response to treatment during initial therapy, time to relapse without treatment, durability and lesional recurrence during maintenance therapy) of V0034 CR 01B cream on uraemic xerosis in the real-life setting.\n\nSecondary objectives:\n\n1. To assess the local tolerance of V0034 CR 01B after long-term use\n2. To assess the patient benefit and acceptability of V0034 CR 01B","primaryOutcome":{"measure":"Treatment Response of Xerosis","timeFrame":"28 days","effectByArm":[{"arm":"V0034CR01B","deltaMin":71,"sd":null},{"arm":"V0034 CR 01B Vehicle","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["39422853"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":118},"commonTop":["Catheter site infection","Urinary track infection","Application site irritation","Hypertension","Application site pruritus"]}}